Revolution Medicines (RVMD) Share-based Compensation (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Share-based Compensation of $87.3 million for Q1 2026, up 248.03% year-over-year from $25.1 million in Q1 2025, and down 9.0% quarter-over-quarter from $95.9 million in Q4 2025.
Revolution Medicines (RVMD) Share-based Compensation (2019 - 2026) Analysis & Trends
Revolution Medicines' Share-based Compensation history runs 8 years deep, the most recent figure standing at $87.3 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 248.03% year-over-year to $87.3 million; the TTM figure through Mar 2026 stood at $151.6 million (up 671.05% YoY), while the FY2025 annual figure was $208.4 million, up 75.42% from the prior year.
- Share-based Compensation for Q1 2026 stood at $87.3 million, down from $95.9 million in the prior quarter.
- The five-year high for Share-based Compensation was $178.5 million in Q2 2025, with the low at -$56.8 million in Q4 2024.
- The 5-year median for Share-based Compensation is $13.7 million (2023), against an average of $46.4 million.
- The sharpest annual moves came in 2022 and 2024: Share-based Compensation plunged 469.21% in 2022, then soared 814.48% in 2024.
- Revolution Medicines' Share-based Compensation stood at -$22.9 million in 2022, then jumped by 51.6% to -$11.1 million in 2023, then sank by 412.53% to -$56.8 million in 2024, then surged by 269.02% to $95.9 million in 2025, then fell by 9.0% to $87.3 million in 2026.
- Business Quant data shows RVMD's Share-based Compensation at $87.3 million in Q1 2026, $95.9 million in Q4 2025, and $177.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 83.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 277.20 Mn |
| Jun 30, 2026 | 277.20 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Mar 31, 2026 | 87.30 Mn |
| Dec 31, 2025 | 95.93 Mn |
| Dec 31, 2025 | 95.93 Mn |
| Sep 30, 2025 | 177.70 Mn |
| Sep 30, 2025 | 177.70 Mn |
| Jun 30, 2025 | 178.50 Mn |
| Jun 30, 2025 | 178.50 Mn |
| Mar 31, 2025 | 25.08 Mn |
| Mar 31, 2025 | 25.08 Mn |
| Dec 31, 2024 | -56.76 Mn |
| Dec 31, 2024 | -56.76 Mn |
| Sep 30, 2024 | 120.80 Mn |
| Sep 30, 2024 | 120.80 Mn |
| Jun 30, 2024 | 118.70 Mn |
| Jun 30, 2024 | 118.70 Mn |
| Mar 31, 2024 | 16.21 Mn |
| Mar 31, 2024 | 16.21 Mn |